Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07777328

The Effect of 5-hydroxytryptophan on ADHD Traits and Eye Movements

The Effect of 5-hydroxytryptophan on ADHD Traits and Eye Movements — Recruiting • Non-phase study • Mental Health / Psychiatry • NCT07777328.

📅 20 Aug 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07777328
Start
2025-11-25
Completion
2027-02
ClinicaliQ Trial Snapshot
  • The Effect of 5-hydroxytryptophan on ADHD Traits and Eye Movements — Recruiting • Non-phase study • Mental Health / Psychiatry • NCT07777328.
  • Trial testing whether a natural supplement (5-HTP) can improve concentration and attention problems by increasing serotonin levels.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The aim of this project is to look at the impact of 5-Hydroxytryptophan (5-HTP) on distractibility. 5-HTP is the precursor to the neurotransmitter serotonin and is a chemical that the body produces naturally. There is evidence that distractibility is associated with a decreased level of serotonin. This research aims to see if giving people 5-HTP will alter their distractibility, which will form part of an initial assessment as to whether 5-HTP could be used to support people with attention problems. The study involves completing a short survey about mental health…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction
Mental Health / Psychiatry · MHRA · 15 Oct 2026
All antidepressants now require enhanced safety communication about risks of suicidal ideation/behaviour and persistent sexual dysfunction to ensure informed patient consent before…
View brief →
Clinical Brief
Autism, ADHD and mental health review: What you need to know
Mental Health / Psychiatry · BBC Health · 09 Oct 2026
Early identification and integrated support across health, education and social care services are essential, as autism and ADHD significantly impact mental health…
View brief →
Clinical Brief
Hidden habits that make your social anxiety worse – and how to break them
Mental Health / Psychiatry · BBC Health · 30 Sep 2026
Social anxiety disorder affects a significant proportion of the population and may be under-recognised in clinical practice; increased awareness of prevalence is…
View brief →
Clinical Brief
Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction
Mental Health / Psychiatry · MHRA · 11 May 2026
The MHRA has identified suicidal thoughts and behaviours as a safety concern with finasteride and dutasteride, requiring additional risk minimisation measures in…
View brief →
Clinical Brief
Report highlights flaws in ADHD and autism care
Mental Health / Psychiatry · BBC Health · 09 Oct 2026
Diagnostic concerns: An official review has identified a risk of over-diagnosis in both ADHD and autism in England, suggesting current diagnostic practices…
View brief →
Clinical Brief
ADHD and autism at risk of over-diagnosis, says government review
Mental Health / Psychiatry · BBC Health · 08 Oct 2026
Risk of over-diagnosis in younger people with ADHD and autism, with society potentially overcorrecting from previous under-diagnosis era Government review highlights need…
View brief →